Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
第五届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the sixth meeting of the fifth Supervisory Board of Meikang Biotechnology Co., Ltd. It details the approval of continuing to use idle raised funds for cash management, including voting results and references to compliance with relevant laws and stock exchange rules. The document is short (1109 characters), contains no financial statements or detailed financial data, and serves as a meeting resolution announcement rather than a full report or financial disclosure. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. It is a formal corporate announcement related to board/supervisory decisions. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-05-21 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司继续使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中天国富证券有限公司) regarding the continued use of idle raised funds by 美康生物科技股份有限公司 for cash management. It references regulatory guidelines, fundraising details, board and supervisory approvals, and risk control measures. The document is not a full financial report but rather a formal verification and opinion on the company's use of idle raised funds for cash management. It includes procedural details, approvals, and compliance with regulatory requirements. This type of document fits best under the category of Regulatory Filings (RNS) because it is a regulatory compliance and verification statement rather than a financial report, earnings release, or capital update. The document length is about 4559 characters, which is substantial but does not contain financial statements or earnings data. Therefore, the classification is RNS with high confidence.
2024-05-21 Chinese
第五届董事会第七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's fifth board of directors' seventh meeting. It includes details about the meeting date, attendance, agenda items, voting results, and mentions compliance with company law and articles of association. The content focuses on board decisions regarding the use of idle raised funds for cash management and authorizations given to management. There is no financial statement or detailed financial data presented, nor is it a report or presentation. It is clearly a Board/Management Information announcement about board meeting resolutions and decisions. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is short and it is not an announcement of a report publication, so RPA is not applicable.
2024-05-21 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by regulatory authorities. It includes details about the certificates, product names, registration numbers, validity periods, intended uses, and a statement on the impact on company performance and risk warning. The document is short (1390 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory approval rather than a financial report or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-21 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificate, product, and potential impact on company performance. The document is short (864 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-04-26 Chinese
关于收到《传票》暨诉讼事项的进展公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from 美康生物科技股份有限公司 regarding the receipt of a court summons (传票) related to ongoing litigation involving the company and its subsidiary. It details the background of the lawsuit, the progress of the case, the amounts involved, and the upcoming court hearing date. There is no financial data, audit results, or management discussion of financial performance. The document is clearly a legal proceeding update rather than a financial report or other corporate filing. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is short (2080 characters), but it contains substantive information about the legal case, not just a notice of report publication or certification, so it is not RPA or RNS.
2024-04-23 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.